Heather Saavedra

Mrs. Heather Saavedra

Department of Pediatrics, The University of Texas Health Science Center at Houston, Houston, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
TDTerry G.J. Derks
Terry G.J. Derks
DRDavid F. Rodriguez-Buritica
David F. Rodriguez-Buritica
AAAyesha Ahmad
Ayesha Ahmad
FBFoekje de Boer
Foekje de Boer
María L. CouceMaría L. Couce
María L. Couce
JMJohn Mitchell
John Mitchell
Glycogen storage disease type Ia (GSDIa) is caused by defective glucose-6-phosphatase, a key enzyme in carbohydrate metabolism. Affected individuals cannot release glucose during fasting and accumulate excess glycogen and fat in the liver and kidney, putting them at risk of severe hypoglycaemia and secondary metabolic perturbations. Good glycaemic/metabolic control through strict dietary treatment and regular doses of uncooked cornstarch (UCCS) is essential for preventing hypoglycaemia and long-term complications. Dietary treatment has improved the prognosis for patients with GSDIa; however, the disease itself, its management and monitoring have significant physical, psychological and psychosocial burden on individuals and parents/caregivers. Hypoglycaemia risk persists if a single dose of UCCS is delayed/missed or in cases of gastrointestinal intolerance. UCCS therapy is imprecise, does not treat the cause of disease, may trigger secondary metabolic manifestations and may not prevent long-term complications. We review the importance of and challenges associated with achieving good glycaemic/metabolic control in individuals with GSDIa and how this should be balanced with age-specific psychosocial development towards independence, management of anxiety and preservation of quality of life (QoL). The unmet need for treatment strategies that address the cause of disease, restore glucose homeostasis, reduce the risk of hypoglycaemia/secondary metabolic perturbations and improve QoL is also discussed.

2 September 2021 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
MFMarta Frigeni
Marta Frigeni
DRDavid F. Rodriguez‐Buritica
David F. Rodriguez‐Buritica
HSHeather Saavedra
Heather Saavedra
KGKathryn A. Gunther
Kathryn A. Gunther
PHPaul R. Hillman
Paul R. Hillman
HNHope Northrup
Hope Northrup

14 August 2021 in Molecular Genetics and Metabolism Reports
Verified
Journal Article
Open access
DADarius Adams
Darius Adams
HAHans Andersson
Hans Andersson
HBHeather Bausell
Heather Bausell
KCKea Crivelly
Kea Crivelly
CECaroline Eggerding
Caroline Eggerding
KWKaleigh Whitehall
Kaleigh Whitehall
To present a case series that illustrates real-world use of pegvaliase based on the initial experiences of US healthcare providers. Sixteen healthcare providers from 14 centers across the US with substantial clinical experience in treating patients with phenylketonuria (PKU) with pegvaliase in the two-plus years since FDA approval (May 2018) provided cases that exemplified important lessons from their initial experiences treating patients with pegvaliase. Key lessons from each case and takeaway points were discussed in both live and virtual meetings. Fifteen cases of adults with PKU (eight males, seven females), representing a spectrum of age (18 to 53 years), previous PKU care, comorbidities, and socioeconomic situations were reviewed and discussed. Full extended case reports are included in the Supplement. The cases showed that treating patients with a daily injectable can be challenging due to a patient's financial problems, treatment challenges, and neuropsychological and psychiatric comorbidities, which can be identified before starting pegvaliase, but do not prohibit successful treatment. The authors agreed that patient education on adverse events (AEs), time to efficacy, dietary changes, and food preparation is an ongoing process that should start prior to initiating pegvaliase treatment. Treatment goals and planned dietary changes once efficacy is reached should be defined prior to treatment initiation and re-evaluated throughout the course of therapy. Each patient's titration schedule and dietary adjustments are unique, depending on occurrence of AEs and individual goals of treatment. Despite the AE profile of pegvaliase, all but two patients remained motivated to continue treatment and achieved efficacy (except one patient in whom titration was still ongoing). AEs occurring early in the treatment pathway may require prolongation of the titration phase and/or concomitant medication use, but do not seem indicative of future tolerability or eventual efficacy. Close follow-up of patients during titration and maintenance to help with dietary changes is important. This case series provides real-world experience on the use of pegvaliase. Until data from registries and independent research become available, the data presented herein can support appropriate management of patients receiving pegvaliase in clinical practice.

31 August 2026 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
PDF file
JMJohn J. Mitchell
John J. Mitchell
JAJose E. Abdenur
Jose E. Abdenur
FBFoekje de Boer
Foekje de Boer
MBMonica Boyer
Monica Boyer
MBMargo Sheck Breilyn
Margo Sheck Breilyn
RCRichard Collis
Richard Collis
Glycogen storage disease type Ia (GSDIa) is a rare, life‐threatening inherited carbohydrate metabolism disorder caused by biallelic pathogenic G6PC gene variants resulting in deficiency of glucose‐6‐phosphatase. DTX401 is an investigational AAV8 vector containing the human G6PC gene. DTX401‐CL301 is a pivotal, phase 3, double‐blind, randomized, placebo‐controlled trial of DTX401 in patients ≥ 8 years with GSDIa. The primary endpoint was percent change from Baseline to Week 48 in daily cornstarch intake for the DTX401 versus placebo group. Participants were randomly assigned (1:1) to blinded DTX401 or placebo. After the 48‐week Primary Efficacy Analysis Period (PEAP), participants crossed over in a blinded manner for an additional 48‐week blinded Crossover Period. Following randomization: 21 participants received DTX401; 25 received placebo. At Week 48, DTX401 treatment resulted in a statistically significant least squares (LS) mean (SE) daily cornstarch intake reduction of 41% (4.6) versus 10% (4.1) for Placebo ( p < 0.0001). Clinical meaningfulness was evidenced by a mean desired percent reduction in daily cornstarch intake among those reporting in Baseline interviews ( n = 33) of 45% (median = 41%). Greater and faster reductions in cornstarch were observed at Week 96 for the Crossover DTX401 group compared with the DTX401 group in the PEAP. The DTX401 safety profile was acceptable, and expected hepatic reactions consisting of transaminase elevations were managed with prophylactic corticosteroids. Treatment with DTX401 resulted in both a statistically significant and clinically meaningful reduction in cornstarch intake in the 48‐week PEAP versus placebo, with greater cornstarch reductions in both groups at Week 96.

25 September 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
MSMary Sowa
Mary Sowa
MBMonica Boyer
Monica Boyer
JGJessica Alissa Green
Jessica Alissa Green
SPSurekha Pendyal
Surekha Pendyal
HSHeather Saavedra
Heather Saavedra
Background: Nutrition management for GSD Type I (GSDI; OMIM #232200, 232220) is complex, with the goal being to maintain euglycemia while minimizing metabolic derangements. Management guidelines were published in 2002 and 2014. However, there is limited information on the nuances of nutrition management and the unique feeding challenges of children. Methods: A REDCap survey focusing on staffing and current practices in the nutrition management of children with GSD I who were <5 years of age was sent to the metabolic dietitian’s listserv and GMDI membership in 8/2023. Results: There were 21 North American respondents. In 17/21 clinics (81%), Prosobee® was the primary choice for infant formula. Dietitians used different methods to determine hourly glucose needs. Fasting recommendations ranged from 1 to 3 h, and the use of nighttime continuous feeding was common. Cornstarch was started between 6 and 12 months of age. Most clinics did not use Glycosade® for children <5 years of age. Oral motor dysfunction, gagging, and lack of interest in food were common. Continuous glucose monitoring (CGM) devices were recommended in 20 clinics (95%). Most clinics followed patients on an outpatient basis. All clinics provided a hypoglycemia management plan; however, there was wide variability in practice. Conclusion: This survey highlights the variability in the care of individuals <5 years of age with GSD I. Updated guidelines are needed to help address the unique nutrition challenges in this age group.

1 January 2021 in Journal of Inborn Errors of Metabolism and Screening
Verified
Journal Article
Open access
AAAnjali Aggarwal
Anjali Aggarwal
HNHope Northrup
Hope Northrup
DRDavid F. Rodriguez-Buritica
David F. Rodriguez-Buritica
SHS. Shahrukh Hashmi
S. Shahrukh Hashmi
HSHeather Saavedra
Heather Saavedra